too less samples. but anyway, it's good news.
who can save us finally, in this tough world...
In the documents I have read for various routes of medication for Hep B, I have not come across any correlation between country and effectiveness -- just variations based on the genotype of Hep B. Having said that, I have seen differences in tolerance profiles -- blacks have different thresholds for WBC counts when considering dosage change for peginterferon.
By no means do I mean to rule out race as a factor -- all I'm saying is that I have not seen good reasons to use race as a factor for the course of our medications.
of course nobody must think to seroconvert under entecavir, percentages are so small but if italian you might consider this study when choosing entecavir or tenofovir and check hbsag baseline and 12 weeks if any hbsag decrease happens since if you fall in the small percentage seroconversion is very fast in the first 1-2 years
on tenofovir the percentage is an absolute 0% at 3 years on hbe negative, so absolutely no chances in this case.but on hbe positive they are similr to interferon with a steady slow hbsag decline
study is only italian and results are to be applied to italy only, it is a research among italian etv patients which are pratically all hbe negative (hbe positive is rare here)
i actually already knew about it from march, the researcher who is following me told me that hbsag kinetics in the first 12 weeks can show if seroconverter or not
Data size may not be enough to be significant. There are thousands of HBVers on entecavir in Chinese HBV site and their HBsAg clearance rate is a long call from that reported in this paper: 100%.
That's interesting. Thank you.